Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors

Helen Fillmore, Michael D. Shultz, Scott C. Henderson, Patricia Cooper, William C. Broaddus, Zhi Jian Chen, Chun-Ying Shu, Jianfei Zang, Jiechao Ge, Harry C. Dorn, Frank Corwin, John Wilson, Panos P. Fatouros

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Glioblastoma multiforme is the most common and most lethal primary brain tumor in humans, with median survival of approximately 1 year. Owing to the ability of glioma cells to aggressively infiltrate normal brain tissue and survive exposure to current adjuvant therapies, there is a great need for specific targeted nanoplatforms capable of delivering both therapeutic and imaging agents directly to invasive tumor cells. 
Method: Gadolinium-containing endohedral fullerenes, highly efficient contrast agents for MRI, were functionalized and conjugated with a tumor-specific peptide and assessed for their ability to bind to glioma cells in vitro. 
Results: We report the successful conjugation of the carboxyl functionalized metallofullerene Gd3N@C80(OH)-26(CH2CH2COOH)-16 to IL-13 peptides and the successful targeting ability towards brain tumor cells that overexpress the IL-13 receptor (IL-13Rα2). 
Conclusion: These studies demonstrate that IL-13 peptide-conjugated gadolinium metallofullerenes could serve as a platform to deliver imaging and therapeutic agents to tumor cells.
Original languageEnglish
Pages (from-to)449-458
JournalNanomedicine
Volume6
Issue number3
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Dive into the research topics of 'Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors'. Together they form a unique fingerprint.

Cite this